Cargando…

PB1961: INVOLVEMENT OF IMMUNITY IN THE CONTINUATION OF TFR AFTER BOSTINIB DISCONTINUATION

Detalles Bibliográficos
Autores principales:	Fujioka, Yuki, Ono, Takaaki, Takahashi, Naoto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429829/ http://dx.doi.org/10.1097/01.HS9.0000974660.30717.74

Ejemplares similares

PB2618: USE AND DISCONTINUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: A SINGLE CENTRE EXPERIENCE
por: Martinez, Celia, et al.
Publicado: (2023)

PB1961: ZNO NANOPARTICLES INDUCE MULTIPLE MYELOMA CELL DEATH BASED ON REACTIVE OXYGEN SPECIES AND CASPASE SIGNALING PATHWAY
por: Li, Z., et al.
Publicado: (2022)

PB1962: INFLUENCE OF TRANSCRIPT TYPES IN SUSTAINED DEEP MOLECULAR RESPONSE (SDMR) AND TREATMENT-FREE REMISSION (TFR) IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS TREATED WITH TKI
por: Torra, Silvia Marce, et al.
Publicado: (2023)

PB1897: DISCONTINUATION OF IMATINIB IN PATIENTS FOLLOWED FOR CHRONIC MYELOID LEUKEMIA IN DEEP MOLECULAR RESPONSE
por: Bouchakor Moussa, Y., et al.
Publicado: (2022)

PB1905: FEASIBILITY OF TREATMENT DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA IN CLINICAL PRACTICE: RESULTS FROM A SERIES OF 19 PATIENTS
por: KACHA, F., et al.
Publicado: (2022)

PB2197: ADULT LANGERHANS CELL HISTIOCYTOSIS WITH LIVER INVOLVEMENT
por: Chang, Long, et al.
Publicado: (2023)

PB2306: RELAPSE OF IMMUNE THROMBOCYTOPENIA AND MYOCARDITIS
por: Kapsouli, F., et al.
Publicado: (2022)

PB2658: IMMUNE THROMBOCYTOPENIC PURPURA IN ALBANIA
por: Grazhdani, Sara, et al.
Publicado: (2023)

PB1931: HEMATOLOGICAL COMPLICATIONS OF COVID IMMUNIZATION-CASE SERIES
por: Aribandi, A., et al.
Publicado: (2022)

PB2685: QUALITY OF LIFE IN INDIAN ADULTS WITH IMMUNE THROMBOCYTOPENIA
por: Bhat, Vivek, et al.
Publicado: (2023)

PB2308: NIVOLUMAB-BASED THERAPY OF RELAPSED OR REFRACTORY PRIMARY LARGE B-CELL LYMPHOMA OF IMMUNE-PRIVILEGED SITES AND DLBCL WITH SECONDARY CNS INVOLVEMENT
por: Gavrilenko, Andrey, et al.
Publicado: (2023)

PB2637: OUR EXPERIENCE WITH AVATROMBOPAG TREATMENT IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA
por: Cervinek, Libor
Publicado: (2023)

PB2623: AVATROMBOPAG FOR THE TREATMENT OF CHILDREN WITH PERSISTENT AND CHRONIC IMMUNE THROMBOCYTOPENIA
por: An, Qi, et al.
Publicado: (2023)

PB2259: MONOCYTE’S INVOLVEMENT IN INFLAMMATORY RESPONSE IN COVID-19 INFECTION IN CHRONIC RENAL DISEASE
por: Bumbea, V., et al.
Publicado: (2022)

PB2402: CLINICAL CHARACTERISTICSAND PROGNOSIS RISK FACTORS OF NON-HODGKIN’S LYMPHOMA INVOLVING THE HEART
por: Chen, Yue, et al.
Publicado: (2023)

PB2036: PERIPHERAL BLOOD CYTOPENIA, AN EARLY INDICATOR OF INBORN ERRORS OF IMMUNITY
por: Chapanduka, Zivanai Cuthbert, et al.
Publicado: (2023)

PB2606: REAL-WORLD EXPERIENCE OF HETROMBOPAG IN RELAPSE AND REFRACTORY IMMUNE THROMBOCYTOPENIA
por: Feng, Yimei, et al.
Publicado: (2023)

PB2534: SARS-COV-2 IMMUNIZATION AFTER VACCINES IN PATIENTS WITH HEMOGLOBINOPATHY: A SINGLE CENTER EXPERIENCE
por: Duminuco, Andrea, et al.
Publicado: (2023)

PB1769: STIM2, A CALCIUM CENSOR POTENTIALLY INVOLVED IN THE PATHOPHYSIOLOGY OF ACUTE MYELOID LEUKEMIA
por: Djordjevic, Stefan, et al.
Publicado: (2023)

PB2301: PEDIATRIC IMMUNE THROMBOCYTOPENIA; A GLANCE AT PATIENTS AND CURRENT THERAPEUTIC CHALLENGES
por: Al-Jadiry, M., et al.
Publicado: (2022)

PB2350: HEMATOLOGIC MALIGNANCIES AND AUTO-IMMUNITY: A CASE SERIES OF 21 PATIENTS
por: Hanani, Hind, et al.
Publicado: (2023)

PB1715: UNLEASHING NATURAL KILLER (NK) CELLS TO PROMOTE ANTI-LEUKEMIC IMMUNITY
por: Tsoukala, Ioanna, et al.
Publicado: (2023)

PB2322: TTP AFTER COVID 19
por: Gagloeva, D., et al.
Publicado: (2022)

PB2316: EFFICACY AND SAFETY OF ELTROMBOPAG IN PEDIATRIC PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA AND ITS EFFECT ON CELLULAR IMMUNE FUNCTION
por: 吴, ?.
Publicado: (2022)

PB2496: CAR-T CELLS THERAPY COMBINED WITH POMALIDOMIDE AGAINST RELAPSE AND REFRACTORY MM OR ALL WITH EXTRAMEDULLARY INVOLVEMENT
por: Zhao, Jie, et al.
Publicado: (2023)

PB2338: BONE MARROW INVOLVEMENT IN KOREAN PATIENTS WITH LYMPHOMAS: A 21-YEAR LARGE SINGLE-CENTER STUDY: Keywords: Lymphoma, Bone marrow involvement
por: Kim, Min-Sun, et al.
Publicado: (2023)

PB2613: PREDICTIVE MODEL TO EVALUATE THE RISK OF IMMUNE THROMBOCYTOPENIA IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
por: Cornudella, Jesus, et al.
Publicado: (2023)

PB2621: TREATMENT OF IMMUNE THROMBOCYTOPENIA WITH HETROMBOPAG—A SINGLE-CENTER RETROSPECTIVE, OBSERVATIONAL STUDY
por: Zhou, Hu, et al.
Publicado: (2023)

PB2616: SYSTEMIC LUPUS ERYTHEMATOSUS RELATED IMMUNE THROMBOCYTOPENIA: A CHARACTERISTIC CLINICAL FENOTIPE
por: Cornudella, Jesus, et al.
Publicado: (2023)

PB2130: RATIONAL FOR METHOTREXATE USAGE FOR THE TREATMENT AND PREVENTION OF CNS INVOLVEMENT IN PATIENTS WITH HIGH-GRADE B-CELL LYMPHOMAS.
por: Misyurina, A., et al.
Publicado: (2022)

PB2070: IMMUNE RESPONSES AFTER SARS-COV-2 MRNA-VACCINATION AND INFECTION AT SINGLE CELL RESOLUTION IN PATIENTS WITH MULTIPLE MYELOMA
por: Enssle, Julius C., et al.
Publicado: (2023)

PB2608: THE MANAGEMENT OF IMMUNE THROMBOCYTOPENIA (ITP) IN NORWAY IN THE REAL LIFE – ANALYSIS OF THE NOR-ITP REGISTRY
por: Ilicheva, Ekaterina, et al.
Publicado: (2023)

PB2124: EFFICACY AND IMMUNE MODULATION OF DARATUMUMAB PLUS IMID COMBINATION IN PATIENTS REFRACTORY TO BOTH AGENTS“
por: Kostopoulos, Ioannis, et al.
Publicado: (2023)

PB2612: UNITED KINGDOM RETROSPECTIVE OBSERVATIONAL STUDY OF ROMIPLOSTIM AND OTHER TREATMENTS IN EARLY IMMUNE THROMBOCYTOPENIA
por: Mcdonald, Vickie, et al.
Publicado: (2023)

PB2362: BEST PRACTICES ON EMPOWERING AND INVOLVING PATIENTS LIVING WITH HEMATOLOGICAL MALIGNANCIES ON THE DEVELOPMENT OF NOVEL PATIENT-REPORTED OUTCOME MEASURES
por: Vrontaras, N., et al.
Publicado: (2022)

PB2213: RETROSPECTIVE ANALYSIS OF 45 UNSELECTED PATIENTS WITH HISTIOCYTOSIS CONFIRMS PROGNOSTIC RELEVANCE OF ORGAN INVOLVEMENT: SINGLE‐CENTER EXPERIENCE
por: Yilmaz, Hulya, et al.
Publicado: (2023)

PB2351: ANXIETY AT THE HEMATOLOGIST
por: Trojan, S., et al.
Publicado: (2022)

PB1952: CLL IN AYA
por: Mohamed, Shehab, et al.
Publicado: (2023)

PB2159: CHARACTERIZATION OF THE IMMUNE RESPONSE DEVELOPED IN PATIENTS WITH MULTIPLE MYELOMA AFTER RECEIVING TWO DOSES OF THE VACCINE AGAINST SARS-COV-2
por: Perez, Laura, et al.
Publicado: (2023)

PB1950: MASS CYTOMETRY ANALYSIS IDENTIFIES T CELL IMMUNE SIGNATURE FOR APLASTIC ANEMIA AND PREDICTS RESPONSE TO CYCLOSPORINE
por: Zhang, L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qig2ps2krg76dv1clheibvjaq3